Related Experiment Video

Updated: Jun 6, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Targeting survivin in cancer: patent review

Jagat R Kanwar1, Sishir K Kamalapuram, Rupinder K Kanwar

  • 1Deakin University, Institute for Technology Research and Innovation (ITRI), Centre for Biotechnology and Interdisciplinary Biosciences (BioDeakin), Laboratory of Immunology and Molecular Biomedical Research (LIMBR), Waurn Ponds, Victoria 3217, Australia. jagat.kanwar@deakin.edu.au

Expert Opinion on Therapeutic Patents
|November 19, 2010
PubMed
Abstract

Insights

Survivin, a key protein in cancer, drives tumor growth and resistance. Targeting survivin expression through various therapies, including nanotechnology, offers a promising strategy to enhance cancer treatment efficacy and induce apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Survivin is a critical anti-apoptotic protein frequently overexpressed in various cancers.
  • Elevated survivin levels contribute to uncontrolled cancer cell proliferation and resistance to therapies.
  • Downregulating survivin can sensitize cancer cells to treatments, promoting apoptosis.

Purpose of the Study:

  • To review current knowledge and patent information regarding survivin.
  • To discuss survivin's role in cancer biology and therapeutic targeting strategies.
  • To highlight recent advancements in survivin-targeted cancer treatments.

Main Methods:

  • Comprehensive analysis of up-to-date survivin patent literature.
  • Detailed discussion of survivin biology and targeting research areas.
  • Review of recent developments in understanding survivin's function in cancer.

Main Results:

  • Recent developments validate treatment paradigms that suppress survivin expression.
  • Various therapeutic platforms show potential for survivin downregulation.
  • Nanotechnology platforms are emerging for site-specific survivin targeting.

Conclusions:

  • Effective survivin downregulation is achievable through diverse therapeutic approaches.
  • Selective targeting of survivin in cancer remains a significant challenge.
  • Nanotechnology offers a promising avenue for precise survivin targeting in tumors.

More Related Videos

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...